Pip: If you have been quietly searching for a treatment that uses your own blood, skips the surgery, and promises results in weeks, you have probably already seen the ads — and Kalpesh Kapadia, uroandrologist in Ahmedabad, has seen the patients those ads send his way.
Mara: This episode follows one substantial post covering P-Shot therapy for erectile dysfunction in Gujarat — what the biology claims, what the trials actually found, and where the evidence genuinely stands today.
Pip: Let's start with what the P-Shot is, who it's for, and whether the story holds up.
P-Shot for ED: What the Evidence Actually Says
Mara: The post opens with a frank framing: men searching for P-Shot therapy in Gujarat are usually looking for two things at once — something that works, and something that avoids daily tablets or surgery. The question is whether one injection can deliver both.
Pip: The post sets up the biology clearly. Platelet-rich plasma is your own blood, spun in a centrifuge to concentrate the platelets, which release growth factors that signal tissue repair and new blood vessel formation. The theory is that injecting this into erectile tissue could address vascular ED at the root cause rather than just managing symptoms temporarily.
Mara: And here is where the post gets direct. On the clinical evidence, it states: "The most rigorous single study — a prospective, randomised, double-blind, placebo-controlled trial published in the Journal of Urology (Masterson et al., 2023) — found PRP injections safe but no more effective than placebo in men with mild-to-moderate ED."
Pip: So the safety record is clean, but the efficacy case has a significant hole in it — and that hole was dug by the study design that's hardest to argue with.
Mara: Right. The post notes that newer pooled analyses from 2025 to 2026, using stricter methodology, have also concluded that platelet-rich therapies do not show superior efficacy over placebo. Both the American Urological Association and the European Association of Urology classify PRP for ED as experimental, recommending it only within clinical trials.
Pip: The post is careful not to dismiss the P-Shot entirely — it notes the safety profile is genuinely reassuring and that some men do report improvement. But it flags the real-world cost: spending between sixty thousand and one lakh twenty thousand rupees on a three-session course before trying treatments with far stronger evidence is, in most cases, the wrong order of operations.
Mara: That ladder of treatments is laid out in detail. PDE5 inhibitors like sildenafil and tadalafil succeed in roughly sixty to seventy percent of men. Intracavernosal injection therapy works in around seventy to eighty percent even in difficult cases. Low-intensity shockwave therapy carries a conditional recommendation from both major guideline bodies — making it the better-supported regenerative option.
Pip: There's also a point that lands harder than the injection debate: in Gujarat's population, with its high burden of type 2 diabetes and metabolic syndrome, a substantial proportion of men presenting with ED have undiagnosed or poorly controlled diabetes, undiagnosed hypertension, or silent cardiovascular disease. An injection into the penis addresses the symptom while the underlying disease continues quietly.
Mara: The post puts it plainly — ED is frequently the first warning sign of cardiovascular disease, sometimes years before a cardiac event. That is why proper evaluation, including history, examination, blood tests, and penile Doppler ultrasound where indicated, matters far beyond the sexual function question.
Pip: So the real ask isn't whether the P-Shot works. It's whether you've found out why your erections changed — because that answer often matters for your heart, your blood sugar, and your overall health.
Mara: And that question about underlying causes points directly to how prevention fits into the picture.
Pip: The thread running through all of this is that the most powerful interventions — stopping tobacco, controlling blood sugar, moving more — cost almost nothing and improve the results of every other treatment.
Mara: The post ends there too: the important step is the first one, which is a proper evaluation, not a product.